PLURNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
Pluri Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 10, 2026
$0.85−0.08 (-8.58%)
Close on Oct 19, 2026
- Market cap
- $9.08M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.3999 (−80.00%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Pluri Inc. saw revenue fall 24.0% to $1.02M over the twelve months to Jun 30, 2026. Free cash flow was -$20.22M.
Revenue
$1.02M
-24.0% vs. a year earlier
Operating income
-$24.94M
TTM Q4 2026
Free cash flow
-$20.22M
TTM Q4 2026
EPS, diluted
-$2.44
FY2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $9.08M
- P/E ratio
- –
- Price to sales
- 8.94
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -222.71%
Fundamentals
- Revenue
- $1.02M
- Net income
- -$23.82M
- EPS, diluted
- -$2.44
- Free cash flow
- -$20.22M
- Book value per share
- -$2.16
- Diluted shares
- 11M
Fifteen years at a glance
Fiscal years 2012 to 2026, USD
Revenue
$1.02M-24.0% YoY
Gross profit
$453.00K-30.7% YoY
Operating income
-$24.94M
Net income
-$23.82M
EPS, diluted
-$2.44
Free cash flow
-$20.22M
Reported period